Launches a wide range of pharmaceuticals in Jammu & Kashmir
By News Agency of Kashmir,
Srinagar : ATLAS Group (Gwalior) having diversified business interests in Bicycle, Steel & e-Bikes has now spread its wings into the burgeoning Indian Pharmaceuticals Industry under its new venture ATLAS Laboratories and Pharmaceuticals Ltd. With a mission to provide better quality medicine at highly affordable prices to the masses, ALPL today announced its entry into Jammu & Kashmir Market and has launched a wide range of medicine targeting mass market.
On the occasion, Ashwani Kapur, Executive Director, ATLAS Laboratories and Pharmaceuticals Ltd said, “Providing affordable medicine to mass market, reflects the ATLAS Group (Gwalior)’s long term commitment towards the common man and our foray into the pharmaceutical industry is also in line with the Indian government’s policy of lowering down the drug prices; perhaps we are the only company who have initiated a step in this direction”.
ALPL has set up one of the most advanced, state-of-the-art manufacturing plants in the country for manufacturing a gamut of pharmaceutical products, at SIDCUL Industrial Area, Hardwar, and Uttarakhand. The plant is designed as per World Health Organization (WHO) norms so as to meet export requirements and it also complies with all the International GMP Standards.
Disclosing the expansion plans of ALPL, Kapur said, “Ours is one of the largest integrated plants in Northern India, which provides almost all facilities under one roof. We have already invested over 100 crores in this plant and a further investment to the tune of 400-500 crores is in the pipeline.” The company is targeting a top line of 500 crores in the next five years.
ALPL plans to enter the ethical market in a big way (Domestic and International). ALPL has recognized opportunities available in international markets and has already been approached by other countries to distribute our medicines. The company is also eyeing OEM in a major way, for capacity utilization and to reach faster breakeven of the project. ALPL is in talks with some of the domestic and International pharmaceutical majors to tie-up for OEM.
Discussing about the marketing network Kapur highlighted, “”Strategically ALPL is spreading its footsteps in a phased manner. After completing phase–I, i.e. North India, the company will enter other parts of the country in Phase-II. This will further help us in making our presence felt in different markets in a more focused manner. Our target is to have a network of over 1000 dealers (1 Lac retail outlets) all across the country in the next 18 months. In North India we intend appointing 250 dealers (30000 retail outlets) to market our products.”
“Presently ALPL has launched 15 products in the market including ATLAKO, an antioxidant with revolutionary contents and exceptional results, which is recommended to be used as a preventive medicine from degenerative diseases considering today’s strenuous lifestyle. In near future ALPL will also come out with advanced molecules and formulation of medicines after rigorous R&D, which will cater to the needs of the masses as well as specific requirements of the classes.” added Kapur.
Some of the products in pipeline are Anti-Hypertensive, Anti-Anginal, Liver Formulation, Pro Biotic, Anti-Psychotic, Hormonal Preparations and Life-style drugs to be launched in the next phase. ALPL is also studying the market to launch life saving drugs in the Cardiovascular and Oncology segments.
Moreover, ALPL has plans to put up a large R&D facility for drug research & discovery in the next phase. It will also enter into collaborations with International companies to launch new molecules in India to provide advanced healthcare solutions to the Indian society.
“India has the potential to be the largest provider of economical cure for ailments, with the talent pool of skills, facilities and sensitivity to find solutions for the industry players as well as consumers”, concluded Kapur.